NA-Semax (N-Acetyl Semax Amidate) is a modified form of Semax, a synthetic heptapeptide analogue of ACTH(4-10) — the biologically active fragment of adrenocorticotropic hormone. Semax itself was developed at the Institute of Molecular Genetics in Moscow and has been registered as a pharmaceutical in Russia since 1994 for neurological and cognitive applications.[1]

The NA-Semax modification adds an N-terminal acetyl group and a C-terminal amide to the native Semax sequence (Met-Glu-His-Phe-Pro-Gly-Pro). These modifications are designed to increase enzymatic stability and potentially enhance blood-brain barrier penetration, extending the functional duration beyond that of unmodified Semax.[2]

Compound Profile

What Does NA-Semax Actually Do?

NA-Semax’s biological activity is inferred primarily from the Semax research literature, as dedicated studies on the N-acetyl amide modification are extremely limited. Semax research demonstrates neuroprotective, nootropic, and immunomodulatory properties through ACTH-related signalling pathways.[1][2]

The parent compound Semax has shown neuroprotective effects in multiple experimental models. Recent research demonstrated Semax’s ability to compensate for gene expression disruption in rat brain following experimental ischaemic stroke, modulating transcriptomic profiles toward recovery patterns within 24 hours of insult.[3] Whether the NA modification enhances these effects, merely extends their duration, or alters the pharmacological profile is not established by direct comparative research.

How NA-Semax Works

The mechanism of action is understood through Semax research, which has identified several molecular pathways:[1][2]

BDNF and neurotrophic signalling: Semax has been shown to upregulate brain-derived neurotrophic factor (BDNF) and other neurotrophic factors. This BDNF-enhancing effect is one of the most consistently reported findings across Semax studies and is considered a key mechanism underlying its neuroprotective and cognitive-enhancing properties.

Gene expression modulation: Large-scale transcriptomic studies have demonstrated that Semax and ACTH-like peptides modulate immune gene expression patterns in brain regions following ischaemia. These peptides appear to compensate for stroke-induced transcriptomic disruption, restoring expression patterns toward baseline.[3][4]

Calcium signalling: Recent research has demonstrated that Semax affects intracellular calcium dynamics in rat brain neurons, suggesting effects on neuronal excitability and signalling at the cellular level.[5]

Opioid receptor interaction: Novel research has identified that Semax targets the mu opioid receptor gene Oprm1, promoting deubiquitination and functional recovery in spinal cord injury models. This previously unrecognised mechanism suggests broader pharmacological activity than initially understood.[6]

Antidepressant and anti-stress effects: Comparative studies have demonstrated antidepressant-like and anti-stress effects of Semax in forced swim and chronic stress paradigms, with efficacy comparable to other ACTH-derived peptides.[7]

The N-acetylation and C-amidation modifications in NA-Semax are standard peptide chemistry approaches to enhance metabolic stability. The acetyl group protects against aminopeptidase degradation at the N-terminus, while the amide protects against carboxypeptidase degradation at the C-terminus.

Longevity / Healthy Aging Context

Semax-derived peptides are investigated within longevity and healthy aging research primarily through the lens of neuroprotection and cognitive preservation. Age-related neurodegenerative decline involves many of the same pathways that Semax modulates — BDNF reduction, neuroinflammation, oxidative stress, and impaired calcium homeostasis.[1]

The neuroprotective effects demonstrated in ischaemic stroke models — gene expression compensation, immune modulation, calcium signalling regulation — are relevant to age-related neurological decline, though the connection is inferential rather than directly demonstrated in aging populations.[3][4]

No clinical longevity studies have been conducted with NA-Semax specifically. The longevity context is extrapolated from acute neuroprotection data in injury models. Compare with Semax, Selank, and Cortexin for related neuroprotective profiles, or see the Longevity / Healthy Aging goal page.

Recovery & Sleep Context

Semax’s demonstrated effects on neurological recovery from ischaemia position it within the recovery research context. The ability to modulate post-ischaemic gene expression toward recovery patterns and reduce inflammatory cascades in brain tissue suggests relevance to neurological recovery processes.[3][4]

The anti-stress and antidepressant-like effects observed in animal models could theoretically influence recovery through stress-axis modulation. Chronic stress impairs recovery processes, and ACTH-derived peptides that modulate HPA axis signalling may indirectly support recovery by reducing stress-mediated interference.[7]

Direct evidence linking NA-Semax to recovery outcomes or sleep quality does not exist. The recovery context for NA-Semax specifically is entirely inferred from parent compound Semax data. See the Recovery & Sleep goal page for broader context.

NA-Semax Benefits

• Enhanced stability: The N-acetyl and C-amide modifications are designed to improve enzymatic resistance compared to unmodified Semax, potentially extending functional duration.
• BDNF upregulation (from Semax data): The parent compound consistently demonstrates BDNF enhancement in preclinical models — one of the most reproducible findings in the Semax literature.[1]
• Neuroprotective gene modulation: Semax compensates for ischaemia-induced transcriptomic disruption, a mechanism with broad relevance to neuroprotection.[3][4]
• Novel opioid receptor mechanism: Recent discovery of mu opioid receptor gene targeting adds a previously unrecognised mechanistic dimension to Semax pharmacology.[6]
• Multi-pathway activity: Unlike single-target compounds, Semax-derived peptides modulate neurotrophic, immune, and calcium signalling pathways simultaneously.[1][5]

NA-Semax Side Effects

No dedicated safety studies for NA-Semax have been conducted. Side effect considerations are inferred from Semax research and general peptide pharmacology:

• ACTH-related effects: As an ACTH(4-10) analogue, theoretical concerns about HPA axis modulation exist, though Semax at studied concentrations did not produce significant cortisol or ACTH-like endocrine effects.
• Nasal irritation: If administered intranasally (the most common Semax delivery route), local mucosal irritation is a theoretical concern.
• Unknown modification effects: The acetylation and amidation modifications could theoretically alter the side effect profile compared to native Semax. No data exists to confirm or rule this out.
• Semax safety record: The parent compound Semax has been used pharmaceutically in Russia since 1994 with reports of generally good tolerability. Whether this safety record transfers to the modified NA form is unconfirmed.

Half-Life

Native Semax has a relatively short half-life, estimated at minutes when administered without modification. The N-acetylation and C-amidation in NA-Semax are specifically designed to extend this duration by protecting against exopeptidase degradation at both termini.

Exact pharmacokinetic data for NA-Semax has not been published. The expected half-life extension from these modifications is modest — likely extending functional activity to the range of hours rather than minutes — based on analogous peptide modification data in the literature.

Limits of Current Evidence

• No dedicated NA-Semax studies: Essentially all evidence is borrowed from the parent Semax literature. NA-Semax has not been independently characterised in published research.
• Modification effects unknown: Whether N-acetylation and C-amidation alter efficacy, selectivity, or side effect profile compared to native Semax is entirely uncharacterised.
• No pharmacokinetic data: The presumed half-life extension has not been measured or published.
• Semax evidence limitations: Even the parent compound’s clinical evidence is predominantly from Russian sources, with limited international replication.
• Nootropic claims exceed data: NA-Semax is marketed in nootropic communities with claims that substantially exceed the available evidence, particularly regarding cognitive enhancement in healthy individuals.

Verdict

NA-Semax is essentially Semax with protective chemical modifications — acetylation and amidation — designed to improve metabolic stability. The parent compound Semax has a legitimate pharmacological pedigree as a Russian-registered pharmaceutical with decades of clinical use and a growing body of mechanistic research including novel findings on opioid receptor targeting and transcriptomic modulation.

However, NA-Semax itself has no independent research characterisation. Every claimed benefit is borrowed from Semax studies. While the chemical modifications are pharmacologically rational and well-established in peptide chemistry, assuming they produce an unambiguously superior compound without data is speculative. For researchers interested in ACTH-derived neuropeptides, the Semax literature provides the evidence base — NA-Semax adds stability engineering but zero additional efficacy data.

FAQ

What is NA-Semax amidate?

NA-Semax amidate (N-Acetyl Semax Amidate) is a chemically modified version of the peptide Semax, a synthetic analogue of ACTH(4-10). The N-acetyl group and C-terminal amide are added to improve enzymatic stability and potentially extend the peptide’s functional duration compared to unmodified Semax.

What is the difference between Semax and NA-Semax?

The difference is chemical modification: NA-Semax adds an acetyl group to the N-terminus and an amide to the C-terminus of the native Semax sequence. These protect against enzymatic degradation, theoretically extending half-life. However, no published studies directly compare their pharmacological profiles, and all efficacy claims for NA-Semax are inferred from Semax research.

Is NA-Semax a nootropic?

NA-Semax is marketed as a nootropic based on the parent compound Semax’s neuroprotective and cognitive research profile, which includes BDNF upregulation and neuroprotective gene modulation. However, no dedicated cognitive enhancement studies have been conducted with NA-Semax specifically, and Semax’s own clinical nootropic evidence is primarily from Russian sources.

What are NA-Semax side effects?

No dedicated safety data exists for NA-Semax. Side effect expectations are based on the parent compound Semax, which has been used pharmaceutically in Russia since 1994 with reports of generally good tolerability. Common theoretical concerns include nasal irritation (if administered intranasally) and potential HPA axis effects.

How does NA-Semax compare to Selank?

Both are synthetic peptides developed in Russia for neurological applications. Semax (and by extension NA-Semax) derives from ACTH(4-10) and is primarily studied for neuroprotection and cognitive enhancement. Selank derives from tuftsin and is primarily studied for anxiolytic and anti-anxiety effects. They target overlapping but distinct neurological domains.

Is NA-Semax approved for medical use?

No. NA-Semax is not approved for medical use in any country. The parent compound Semax is registered as a pharmaceutical in Russia for neurological indications, but this regulatory status does not extend to the NA-modified analogue.

References

1. Radchenko AI. The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model. Acta Naturae. 2025. PMID: 41479572
2. Giri S, et al. Modulation of neuropathological pathways by bioactive peptides and proteins/polypeptides: Targeting oxidative stress in neurodegenerative diseases. Neuropeptides. 2025. PMID: 41004910
3. Filippenkov IB, et al. ACTH-like Peptides Compensate Rat Brain Gene Expression Profile Disrupted by Ischemia a Day After Experimental Stroke. Biomedicines. 2024. PMID: 39767736
4. Filippenkov IB, et al. Synthetic Adrenocorticotropic Peptides Modulate the Expression Pattern of Immune Genes in Rat Brain. Genes. 2023. PMID: 37510287
5. Kolbaev SN. The Effect of Peptide Semax, an ACTH(4-10) Analogue, on Intracellular Calcium Dynamics in Rat Brain Neurons. Bull Exp Biol Med. 2025. PMID: 41171324
6. Liu R, et al. Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury. Br J Pharmacol. 2025. PMID: 40692165
7. Inozemtseva LS, et al. Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II. Eur J Pharmacol. 2024. PMID: 39442746

Cortexin is a complex neuropeptide preparation derived from the cerebral cortex of cattle and pigs. Unlike single-sequence peptides, cortexin contains a mixture of low-molecular-weight polypeptides (molecular weight up to 10 kDa), amino acids, vitamins, and trace minerals extracted through a standardised purification process. It has been registered as a pharmaceutical preparation in Russia and several CIS countries since 1999, primarily for neurological indications.[1][2]

Research interest in cortexin centres on its multi-target neuroprotective profile — rather than acting through a single receptor, the peptide mixture appears to modulate multiple pathways simultaneously, including apoptosis inhibition, antioxidant defence, and neurotrophic factor expression. This polypharmacological approach distinguishes cortexin from single-peptide neuroprotective agents.[1]

Compound Profile

What Does Cortexin Actually Do?

Cortexin research demonstrates a multi-modal neuroprotective profile. In preclinical models of cerebral ischaemia, cortexin reduced infarct volume, improved neurological deficit scores, and preserved memory function. Comparative studies with cerebrolysin and actovegin showed cortexin produced comparable or superior protective effects on memory and cerebral circulation markers.[3]

The peptide preparation has been investigated across a range of neurological conditions in clinical settings, including ischaemic stroke, traumatic brain injury, cognitive impairment, and paediatric neurodevelopmental conditions. Russian-language clinical literature reports consistent improvement in cognitive scores and neurological function, though these studies vary in methodological rigour by Western trial standards.[4]

How Cortexin Works

Cortexin’s mechanism of action involves multiple convergent neuroprotective pathways, consistent with its multi-peptide composition. Research has identified several key molecular targets:[1][2]

Anti-apoptotic activity: Cortexin inhibits brain caspase-8, a key initiator of the extrinsic apoptosis pathway. This anti-apoptotic effect is particularly relevant in ischaemic brain injury, where delayed neuronal death through caspase cascades significantly expands initial lesion size.[5]

Antioxidant defence: Comparative studies demonstrated cortexin’s antioxidant effects in chronic cerebrovascular insufficiency models, with efficacy comparable to cerebrolysin in reducing oxidative stress markers. The antioxidant mechanism appears to involve both direct radical scavenging and upregulation of endogenous antioxidant enzymes.[4]

Neurotrophic factor modulation: Cortexin has been shown to influence BDNF (brain-derived neurotrophic factor) levels and modulate epigenetic mechanisms including expression of the neuroprotective protein FKBP1b — a regulator of calcium signalling implicated in age-related cognitive decline.[6]

Ion channel modulation: Recent research demonstrated cortexin modulates OPG/RANK/RANKL signalling and TRPC1 (transient receptor potential canonical 1) expression in cerebral ischaemia-reperfusion injury, suggesting effects on calcium homeostasis and neuroinflammatory cascades.[7]

Longevity / Healthy Aging Context

Cortexin’s neuroprotective profile positions it within longevity and healthy aging research, particularly regarding cognitive preservation during aging. The peptide’s effects on BDNF levels, caspase inhibition, and antioxidant defence are all relevant to age-related neurodegeneration mechanisms.[1][6]

Russian gerontological research has investigated cortexin alongside other bioregulatory peptides (including Epithalon and thymalin) within a broader framework of peptide bioregulation theory. This research tradition, led by the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology, proposes that short peptides derived from organ-specific extracts can restore age-related functional decline in their tissue of origin.[6]

However, rigorous longitudinal studies demonstrating cortexin’s effects on cognitive aging trajectories in healthy populations are lacking. The longevity context is extrapolated from acute neuroprotection data rather than demonstrated in aging-specific endpoints. See the Longevity / Healthy Aging goal page for broader context. Compare with Humanin and Epithalon for related neuroprotective and longevity-focused profiles.

Recovery & Sleep Context

Cortexin’s most clinically documented application falls within the recovery context — specifically, neurological recovery following ischaemic stroke and traumatic brain injury. Russian clinical studies report improved neurological deficit scores and cognitive recovery timelines when cortexin is added to standard rehabilitation protocols.[3][4]

A prospective, double-blinded comparative study assessed cortexin alongside cerebrolysin and other neuropeptide preparations in neurological recovery contexts, providing some of the more methodologically rigorous evidence available for the compound.[8]

Direct evidence for cortexin effects on sleep architecture is limited. The recovery context is derived primarily from neurological rehabilitation data rather than sleep-specific endpoints. See the Recovery & Sleep goal page for broader context.

Cortexin Benefits

• Multi-target neuroprotection: Research demonstrates simultaneous action on apoptosis, oxidative stress, neurotrophic signalling, and calcium homeostasis — a polypharmacological profile uncommon in single-peptide agents.[1][2][7]
• Clinical track record: Registered pharmaceutical in Russia/CIS since 1999 with extensive clinical use in neurology departments, providing real-world safety and efficacy observations beyond preclinical data alone.
• Caspase-8 inhibition: Direct inhibition of the extrinsic apoptosis initiator represents a specific, validated molecular mechanism for cortexin’s neuroprotective effects.[5]
• Comparative efficacy data: Head-to-head preclinical comparisons with cerebrolysin and actovegin provide context for cortexin’s relative efficacy within the brain peptide extract class.[3][4]
• Neuropathy protection: Preclinical data demonstrates cortexin ameliorates high glucose-induced neuropathy in sensory neurons, suggesting applications beyond ischaemic injury.[9]

Cortexin Side Effects

Cortexin has accumulated a substantial clinical safety record through its pharmaceutical use in Russia and CIS countries. Reported adverse effects include:

• Injection site reactions: Local pain, redness, or swelling at intramuscular injection sites — the most commonly reported adverse effect.
• Allergic reactions: Rare hypersensitivity reactions have been reported, consistent with the animal-derived protein composition of the preparation.
• Prion risk (theoretical): As a bovine/porcine brain-derived product, theoretical concerns about transmissible spongiform encephalopathy exist, though no cases have been reported and manufacturing processes include purification steps designed to reduce this risk.
• Generally well-tolerated: Clinical studies consistently report low discontinuation rates due to adverse events, with the safety profile described as favourable relative to other neuroactive medications.

Half-Life

As a complex multi-peptide mixture, cortexin does not have a single defined pharmacokinetic half-life. The constituent polypeptides have varying molecular weights (up to 10 kDa) and would be expected to have different clearance rates. Clinical dosing protocols typically use once-daily intramuscular injection over courses of 10–20 days, suggesting the biological effects are cumulative rather than dependent on sustained plasma levels of any single component.

Limits of Current Evidence

• Limited Western clinical trials: The vast majority of clinical evidence is published in Russian-language journals, with few studies meeting Western regulatory trial design standards (randomisation, blinding, adequate power).
• Complex composition: As a multi-component extract, identifying which specific peptides drive biological activity is challenging. Batch-to-batch compositional variability is a concern.
• Regulatory status: Not approved by the FDA, EMA, or other major Western regulatory bodies. Registered only in Russia and select CIS/Asian countries.
• Publication bias: Clinical literature is predominantly from research groups with commercial or institutional relationships to cortexin production, raising standard conflict-of-interest considerations.
• Comparator limitations: Most comparative studies test cortexin against other neuropeptide preparations (cerebrolysin, actovegin) rather than against placebo in adequately powered designs.

Verdict

Cortexin occupies an interesting position in the neuropeptide landscape — a multi-component brain extract with genuine molecular mechanisms (caspase-8 inhibition, BDNF modulation, TRPC1 regulation) and decades of clinical use in Russian neurology, yet limited acceptance in Western medicine due to insufficient trial evidence meeting international standards.

The preclinical data is scientifically credible, with mechanisms validated in reproducible models. However, the translational confidence requires acknowledging that clinical evidence is largely confined to Russian-language literature with variable methodological quality. For researchers interested in polypharmacological neuroprotection, cortexin provides a documented example of the multi-peptide approach — but evidence confidence should reflect the geographical and methodological limitations of the clinical data.

FAQ

What is cortexin peptide?

Cortexin is a complex neuropeptide preparation derived from the cerebral cortex of cattle and pigs. It contains a mixture of low-molecular-weight polypeptides (up to 10 kDa), amino acids, vitamins, and trace minerals. It has been registered as a pharmaceutical in Russia since 1999 for neurological conditions.

Is cortexin a nootropic?

Cortexin is classified as a neuroprotective and nootropic agent in Russian pharmacology. Research suggests it modulates multiple neuroprotective pathways including anti-apoptotic activity, antioxidant defence, and neurotrophic factor expression. However, its classification as a nootropic is based primarily on Russian clinical literature rather than international regulatory evaluation.

What are cortexin side effects?

The most commonly reported side effects of cortexin are injection site reactions (pain, redness) from intramuscular administration. Rare allergic reactions have been documented. Clinical studies in Russia report generally favourable tolerability with low discontinuation rates due to adverse events.

How does cortexin compare to cerebrolysin?

Both are animal-derived brain peptide preparations. Cerebrolysin is derived from porcine brain and has more extensive Western clinical trial data, including large stroke trials. Cortexin is derived from bovine/porcine cerebral cortex and has broader Russian clinical use. Preclinical comparative studies show similar efficacy profiles with some differences in specific neuroprotective endpoints.

Is cortexin approved by the FDA?

No. Cortexin is not approved by the FDA, EMA, or other major Western regulatory agencies. It is registered as a pharmaceutical preparation in Russia and several CIS countries, where it has been used clinically since 1999.

What is cortexin mechanism of action?

Cortexin acts through multiple converging mechanisms: inhibition of brain caspase-8 (anti-apoptotic), antioxidant defence enhancement, BDNF modulation, TRPC1/calcium channel regulation, and epigenetic modulation of neuroprotective proteins like FKBP1b. This multi-target profile reflects its complex multi-peptide composition.

References

1. Gulyaeva NV. Molecular mechanisms of brain peptide-containing drugs: cortexin. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2018. PMID: 30499504
2. Kuznik BI. Epigenetic Mechanisms of Peptide-Driven Regulation and Neuroprotective Protein FKBP1b. Molekuliarnaia Biologiia. 2019. PMID: 31099784
3. Tyurenkov IN, et al. Comparative study of protective effects of Cortexin, Cerebrolysin and Actovegin on memory impairment, cerebral circulation and brain morphology. Zhurnal Nevrologii i Psikhiatrii. 2020. PMID: 32929929
4. Kurkin DV, et al. Antioxidant effect of cortexin, cerebrolysin and actovegin in rats with chronic cerebrovascular insufficiency. Zhurnal Nevrologii i Psikhiatrii. 2021. PMID: 34460162
5. Yakovlev AA. Peptide drug cortexin inhibits brain caspase-8. Biomeditsinskaia Khimiia. 2017. PMID: 28251948
6. Kuznik BI. Epigenetic Mechanisms of Peptide-Driven Regulation and Neuroprotective Protein FKBP1b. Molekuliarnaia Biologiia. 2019. PMID: 31099784
7. Guven C. Cortexin modulates OPG/RANK/RANKL and TRPC1 expression in cerebral ischemia-reperfusion injury. Neurological Research. 2026. PMID: 40783844
8. Zhang L, et al. Prospective, double blinded, comparative assessment of the pharmacological activity of Cerebrolysin and distinct peptide preparations. J Neurol Sci. 2019. PMID: 30665068
9. Yazar U. Cortexin ameliorates high glucose-induced neuropathy in cultured rat sensory neurons. Neuroendocrinology. 2023. PMID: 37080184

Dihexa — formally named N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide and also known as PNB-0408 — is a synthetic, metabolically stable analog of angiotensin IV. It was designed by Joseph Harding’s laboratory at Washington State University as part of a programme exploring angiotensin IV derivatives for procognitive applications. Unlike natural angiotensin IV, which is rapidly degraded by peptidases, dihexa was engineered with modifications at both termini to resist enzymatic breakdown.

Key identifiers for the dihexa peptide include CAS number 1401708-83-5, molecular formula C₂₁H₃₃N₃O₄, and molecular weight 395.50 g/mol. It is covered by US Patent 8,673,848. The compound is classified as an HGF mimetic — a molecule that amplifies the activity of hepatocyte growth factor at its c-Met receptor, rather than directly activating the receptor itself.

It is essential to note that dihexa is not approved by the FDA or any regulatory agency for human use. It remains exclusively a research tool, and the published evidence base is extremely limited — consisting primarily of papers from the Harding laboratory at WSU, with minimal independent replication.

Mechanism of Action

The proposed dihexa mechanism centres on potentiation of the dihexa HGF/c-Met signalling pathway rather than direct receptor agonism. According to the originating research, dihexa binds to hepatocyte growth factor and stabilises its dimerisation, facilitating more effective engagement with the c-Met receptor on neurons. This is a fundamentally different approach from conventional neurotrophic peptides like BDNF or NGF, which bind directly to their own receptors.

In the primary research paper (McCoy et al., 2013), dihexa was reported to promote dendritic spine formation (spinogenesis) and dendritic branching in hippocampal neuron cultures. The compound was also reported to facilitate synaptogenesis — the formation of new synaptic connections — through downstream activation of c-Met signalling cascades including PI3K/Akt and MAPK/ERK pathways.

These molecular mechanisms are proposed to underlie dihexa cognitive effects observed in animal models. However, it must be noted that the key mechanistic paper (Benoist et al., 2014; PMID 25187433) linking dihexa’s procognitive effects to HGF/c-Met activation was retracted in 2025 by the Journal of Pharmacology and Experimental Therapeutics, and the original McCoy 2013 paper (PMID 23055539) received a formal expression of concern from the same journal. These retractions significantly weaken confidence in the proposed mechanism.

The HGF/c-Met Pathway

To understand the theoretical basis for dihexa, it helps to examine the HGF/c-Met pathway itself. Hepatocyte growth factor (HGF) — despite its liver-centric name — is expressed widely throughout the central nervous system. It acts through the c-Met receptor (also called MET), a receptor tyrosine kinase involved in cell survival, proliferation, motility, and morphogenesis.

In the brain, HGF/c-Met signalling has been implicated in neuroplasticity, neuronal survival, and synaptic function. Wright and Harding (2011) reviewed the role of the brain renin-angiotensin system and proposed that angiotensin IV’s cognitive effects were mediated through HGF/c-Met rather than traditional angiotensin receptors — a hypothesis that formed the intellectual foundation for dihexa’s development.

Wright and Harding (2015) further elaborated on the brain HGF/c-Met system as a potential therapeutic target for Alzheimer’s disease, arguing that compounds enhancing this pathway could promote neuronal repair and synaptogenesis in neurodegeneration. This remains a theoretical framework that has not been validated in human clinical trials.

Importantly, the HGF/c-Met pathway is also a well-established oncogenic signalling axis. Dysregulated c-Met activation is implicated in tumour growth, invasion, and metastasis across multiple cancer types. This creates a fundamental safety tension: any compound that potentiates HGF/c-Met signalling for neuroprotective purposes may simultaneously carry risks of promoting tumour development. This concern is discussed further in the safety section below. For contrast, neuroprotective peptides like Semax and Selank operate through entirely different mechanisms — primarily BDNF upregulation and GABAergic modulation — without engaging known oncogenic pathways.

Cognitive Enhancement Research

The primary evidence for dihexa as a cognitive enhancer comes from the McCoy et al. (2013) paper, which tested the compound in rats using the scopolamine-induced amnesia model and a bilateral hippocampal-cannulated spatial learning task. The researchers reported that dihexa restored spatial memory performance in scopolamine-treated animals and enhanced learning in normal aged rats when delivered both intracerebroventricularly and — notably — orally.

The claim of oral activity was significant because it suggested the compound could cross the blood-brain barrier, a major practical advantage over larger peptides. The researchers also reported that dihexa was effective at very low doses, which they attributed to its mechanism of potentiating endogenous HGF rather than acting as a direct agonist.

An independent systematic review by Ho and Nation (2018) examined the cognitive benefits of angiotensin IV and related analogs across published experimental studies. While this review covered the broader angiotensin IV field rather than dihexa specifically, it noted that angiotensin IV analogs showed procognitive effects in various memory paradigms. Critically, this review also highlighted the very limited number of research groups studying these compounds and the absence of clinical translation.

Wright and Harding (2019) published a subsequent review in the Journal of Alzheimer’s Disease summarising the brain renin-angiotensin system’s contributions to memory and cognition, including discussion of dihexa’s animal data. This review, however, comes from the same laboratory that developed the compound and does not constitute independent verification.

Alzheimer’s Disease Model Research

The Harding laboratory positioned dihexa as a potential anti-dementia agent, testing it in animal models relevant to Alzheimer’s disease. Wright and Harding (2015) reviewed the theoretical rationale for targeting HGF/c-Met in AD, arguing that deficits in this pathway contribute to synaptic loss — a hallmark of Alzheimer’s pathology that correlates more closely with cognitive decline than amyloid plaque burden.

Wright, Kawas, and Harding (2015) published a broader review in Progress in Neurobiology describing the development of small-molecule angiotensin IV analogs, including dihexa, for treating Alzheimer’s and Parkinson’s diseases. They reported that dihexa reversed cognitive deficits in aged rats and in scopolamine-treated models, framing these results as preclinical proof-of-concept.

However, no Alzheimer’s disease transgenic mouse studies or clinical trials in AD patients have been published. The preclinical data remains confined to pharmacological impairment models (scopolamine) and aged rats — models that have well-documented limitations in predicting clinical efficacy for neurodegenerative diseases. Decades of AD research have shown that compounds effective in these simpler models frequently fail in human trials. Peptides like Cerebrolysin, by comparison, have been tested in human AD patients — though even those results remain debated.

The “10 Million Times More Potent” Claim

Perhaps the most widely circulated claim about dihexa is that it is “ten million times more potent than BDNF” — a statement that requires careful contextualisation to avoid serious misinterpretation.

This claim originates from the McCoy et al. (2013) paper, where the researchers compared the effective concentrations of dihexa and BDNF required to promote dendritic branching in cultured hippocampal neurons. Dihexa reportedly showed activity at picomolar concentrations (10⁻¹² M), while BDNF required nanomolar concentrations (10⁻⁵ M range) — yielding an approximate 10⁷-fold difference in effective concentration for this specific in vitro assay.

Critical caveats that are almost always omitted from popular discussion:

• This is an in vitro comparison only — it reflects dendritic branching in a cell culture dish, not cognitive enhancement in a living organism.
• Dihexa and BDNF work through completely different mechanisms — dihexa potentiates HGF/c-Met while BDNF activates TrkB receptors. Comparing their potencies is like comparing the effective concentration of petrol and an electric charge for starting an engine.
• “More potent” does not mean “more effective” — a lower effective concentration tells you nothing about maximum efficacy, duration of effect, or clinical relevance.
• The comparison has not been independently replicated — it comes from a single experiment in a single paper from the developing laboratory.
• The paper carrying the claim has received a formal expression of concern from the publishing journal.

Responsible interpretation: dihexa appears to promote dendritic branching at much lower concentrations than BDNF in cell culture. Whether this translates to any meaningful cognitive advantage in a living organism — let alone a human — is entirely unknown.

Side Effects & Safety Concerns

There is no human safety data for dihexa. The compound has never been administered to humans in any clinical trial or formal safety study. Any discussion of dihexa side effects must therefore be framed around theoretical risks and the known biology of its target pathway.

The most significant theoretical concern is cancer risk. The HGF/c-Met pathway is one of the most well-characterised oncogenic signalling systems in cancer biology. Aberrant c-Met activation drives tumour growth, angiogenesis, invasion, and metastasis in cancers including lung, gastric, hepatocellular, renal, and breast carcinomas. Major pharmaceutical companies have invested billions in developing c-Met inhibitors as anti-cancer agents. A compound specifically designed to potentiate HGF/c-Met signalling therefore carries an inherent theoretical risk of promoting tumourigenesis, particularly with chronic exposure.

Notably, the Harding laboratory itself published work on HGF mimetics as potential anti-cancer agents (Kawas et al., 2011) — compounds designed to inhibit rather than potentiate c-Met. This illustrates the dual nature of the pathway: the same research group developed both activators (dihexa, for cognition) and inhibitors (for cancer) of the same system. However, this anti-cancer paper (PMID 21859930) was subsequently retracted in 2025.

Additional dihexa side effects concerns include:

• Unknown long-term neurotoxicity — chronic potentiation of any growth factor pathway could have unpredictable effects on neural architecture
• No established dose-response relationship in living organisms beyond limited animal data
• No drug interaction data
• No reproductive toxicity data
• Quality control uncertainty — as an unregulated research chemical, product purity and identity cannot be assumed

The absence of safety data is not evidence of safety. Given the oncogenic potential of its target pathway and the retraction of key supporting papers, the risk-benefit profile of dihexa is highly uncertain.

Pharmacokinetics

Dihexa was specifically engineered for metabolic stability. Unlike natural angiotensin IV (a tetrapeptide rapidly degraded by aminopeptidases), dihexa incorporates protective modifications — an N-terminal hexanoic acid cap and a C-terminal aminohexanoic amide extension — designed to resist enzymatic cleavage.

The McCoy et al. (2013) paper reported that dihexa was orally active in rats, suggesting meaningful absorption from the gastrointestinal tract and penetration across the blood-brain barrier (BBB). If confirmed, this would distinguish it from most peptide-based compounds, which typically require injection or intranasal delivery. However, formal pharmacokinetic parameters — including bioavailability, half-life, volume of distribution, and clearance — have not been published.

The compound’s small size (395.50 g/mol) and relatively lipophilic character are consistent with potential oral absorption and BBB penetration, but the absence of characterised pharmacokinetic data means its half-life remains unknown. No studies have examined dose-response relationships, tissue distribution, or metabolite profiles in any species.

Compound Profile

FAQ

What are the benefits of dihexa?

Proposed dihexa benefits are entirely based on animal and in vitro research. In rat studies, dihexa was reported to enhance spatial memory, reverse scopolamine-induced amnesia, and promote new synaptic connections through HGF/c-Met pathway potentiation. However, no human trials have confirmed any cognitive benefit, and key supporting papers have been retracted or flagged with expressions of concern. Any claimed benefits remain unverified hypotheses.

Is dihexa safe?

There is no human safety data for dihexa. The compound has never undergone clinical trials, formal toxicology assessment, or any regulatory safety review. The most significant theoretical concern is cancer risk, since the HGF/c-Met pathway it potentiates is a well-established oncogenic signalling system. Without safety data, no meaningful risk assessment can be made.

How does dihexa compare to other nootropic peptides?

Dihexa has the weakest evidence base of any commonly discussed nootropic peptide. Unlike Semax (approved in Russia, with multiple clinical studies) or Cerebrolysin (tested in thousands of human subjects), dihexa has never been administered to humans in any published study. Its mechanism — HGF/c-Met potentiation — is also unique among nootropic peptides, which carries both potential novelty and unknown risk.

Is dihexa really 10 million times more potent than BDNF?

This claim refers specifically to the concentration required to promote dendritic branching in hippocampal cell cultures — not to any measure of cognitive enhancement. Dihexa and BDNF act through entirely different receptor systems, making direct potency comparisons largely meaningless. The claim has not been independently replicated, and the paper it originates from has received a formal expression of concern.

Can dihexa be taken orally?

Animal studies reported oral activity for dihexa in rats, suggesting it may cross the blood-brain barrier when taken by mouth. However, formal pharmacokinetic data has not been published, and oral bioavailability has not been quantified. These are preliminary observations in rodents, not established pharmacological parameters.

What is PNB-0408?

PNB-0408 is the research designation for dihexa. The name derives from its development at the Pacific Northwest Biotechnology laboratory (the Harding lab’s commercial entity). The compound’s full chemical name is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, with CAS number 1401708-83-5.

Why have dihexa papers been retracted?

Several papers from the Harding laboratory have been retracted or flagged by the Journal of Pharmacology and Experimental Therapeutics. The Benoist et al. (2014) paper on dihexa’s procognitive and synaptogenic effects was retracted in 2025, and the McCoy et al. (2013) foundational paper received a formal expression of concern. Related papers on angiotensin IV analogs from the same group have also been retracted. These actions significantly undermine confidence in the published dihexa evidence base.

Is dihexa FDA approved?

No. Dihexa is not approved by the FDA, EMA, or any regulatory agency worldwide. It has never entered clinical trials in humans. It remains an early-stage research compound with no path to regulatory approval currently visible in the published literature.

References

1. McCoy AT, Benoist CC, Wright JW, et al. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. J Pharmacol Exp Ther. 2013;344(1):141-154. doi:10.1124/jpet.112.199497. PMID: 23055539. [Expression of concern issued]
2. Benoist CC, Kawas LH, Zhu M, et al. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-Met system. J Pharmacol Exp Ther. 2014;351(2):390-402. doi:10.1124/jpet.114.218735. PMID: 25187433. [Retracted 2025]
3. Wright JW, Harding JW. Brain renin-angiotensin—a new look at an old system. Prog Neurobiol. 2011;95(1):49-67. doi:10.1016/j.pneurobio.2011.07.001. PMID: 21777652.
4. Wright JW, Harding JW. The brain hepatocyte growth factor/c-Met receptor system: a new target for the treatment of Alzheimer’s disease. J Alzheimers Dis. 2015;45(4):985-1000. doi:10.3233/JAD-142814. PMID: 25649658.
5. Wright JW, Kawas LH, Harding JW. The development of small molecule angiotensin IV analogs to treat Alzheimer’s and Parkinson’s diseases. Prog Neurobiol. 2015;125:26-46. doi:10.1016/j.pneurobio.2014.11.004. PMID: 25455861.
6. Ho JK, Nation DA. Cognitive benefits of angiotensin IV and angiotensin-(1-7): a systematic review of experimental studies. Neurosci Biobehav Rev. 2018;92:209-225. doi:10.1016/j.neubiorev.2018.05.005. PMID: 29733881.
7. Wright JW, Harding JW. Contributions by the brain renin-angiotensin system to memory, cognition, and Alzheimer’s disease. J Alzheimers Dis. 2019;67(2):469-480. doi:10.3233/JAD-181035. PMID: 30664507.

Cerebrolysin (FPF-1070) is not a single peptide but a standardised mixture of low-molecular-weight neuropeptides and free amino acids derived from porcine brain tissue through controlled enzymatic proteolysis. The cerebrolysin peptide preparation is manufactured by EVER Neuro Pharma (Austria) and represents one of the most extensively studied neurotrophic preparations in clinical medicine — a biological product rather than a synthetic compound. Unlike single-peptide research compounds such as Selank or GHK-Cu, cerebrolysin delivers a complex cocktail of peptide fragments with neurotrophic factor-like activity, including BDNF-like, GDNF-like, and CNTF-like components.

Cerebrolysin is approved in over 30 countries across Europe, Asia, and Latin America for neurological conditions including ischaemic stroke recovery, traumatic brain injury (TBI), and various forms of dementia. It is not approved by the FDA or MHRA and remains research-use-only in the United States and United Kingdom. Despite this regulatory gap, cerebrolysin has accumulated one of the largest clinical evidence bases of any neurotrophic preparation, including multiple Cochrane systematic reviews.

The distinction between cerebrolysin and most peptides on this site is important: where compounds like BPC-157 or TB-500 are defined single-sequence peptides, the cerebrolysin peptide preparation is a biological product containing hundreds of peptide fragments acting through multiple neurotrophic pathways simultaneously.

Compound Profile

What Does Cerebrolysin Actually Do?

Cerebrolysin delivers a cocktail of neurotrophic peptide fragments that mimic endogenous brain growth factors — specifically brain-derived neurotrophic factor (BDNF), glial cell-derived neurotrophic factor (GDNF), and ciliary neurotrophic factor (CNTF). It provides small protein fragments that the brain normally produces to support neuronal survival, maintain synaptic connections, and promote new neural pathways. The preparation’s peptide components (all under 10 kDa) are designed to cross the blood-brain barrier.

The multi-target approach distinguishes cerebrolysin from single-peptide compounds. Where sermorelin acts through one receptor system, cerebrolysin simultaneously engages multiple neurotrophic signalling cascades — potentially advantageous for complex neurological conditions where damage spans multiple cellular pathways.

Clinical research has centred on three primary contexts: recovery after ischaemic stroke, neuroprotection following traumatic brain injury, and cognitive support in vascular dementia and Alzheimer’s disease. The evidence base includes randomised controlled trials, observational studies, and multiple Cochrane systematic reviews providing independent assessment of evidence quality.

How Cerebrolysin Works

Cerebrolysin’s mechanism of action operates through neurotrophic factor mimicry. The preparation contains peptide fragments that activate the same downstream signalling pathways as endogenous neurotrophic factors — principally the BDNF/TrkB, GDNF/GFRα, and CNTF/CNTFRα receptor systems. Rejdak et al. (2023) provided a comprehensive analysis of how cerebrolysin modulates neurotrophic factor expression in the context of dementia, stroke, and TBI, demonstrating that the compound influences multiple neurotrophic cascades simultaneously rather than targeting a single pathway.[1] This multi-pathway engagement explains the breadth of clinical conditions in which cerebrolysin has been studied.

At the cellular level, cerebrolysin promotes neuronal survival through anti-apoptotic signalling, supports synaptic plasticity by enhancing long-term potentiation mechanisms, and stimulates neurogenesis — the formation of new neurons from neural stem cells. Fiani et al. (2021) reviewed the comprehensive literature on cerebrolysin’s mechanisms across stroke, neurodegeneration, and traumatic brain injury, noting consistent signals for neuroprotective and neuroregenerative activity across diverse experimental models.[2] The biological rationale is that damaged or degenerating neural tissue requires neurotrophic support, and cerebrolysin provides this through a preparation that mimics the brain’s own growth factor repertoire.

The multi-target nature creates both advantages and interpretive challenges. Complex neurological injuries affect multiple cell types and pathways, and a multi-target intervention matches this complexity. However, attributing observed clinical effects to specific mechanisms is more difficult with a mixture than with a defined single compound like ipamorelin or GHK-Cu, where structure-activity relationships are clearer.

Neuroprotection Context

Neuroprotection represents the primary research domain for cerebrolysin, with the strongest clinical evidence base concentrated in ischaemic stroke and traumatic brain injury. The cerebrolysin stroke research literature is particularly extensive, spanning multiple randomised controlled trials and Cochrane-level systematic review. Cook et al. (2025) included cerebrolysin in their updated review of neuroprotective strategies after traumatic brain injury, recognising its position within the broader landscape of agents studied for post-TBI neuroprotection.[3]

The Cochrane systematic review by Ziganshina et al. (2023) represents the most rigorous independent evaluation of cerebrolysin for acute ischaemic stroke. The review concluded that the evidence for clinical benefit remained uncertain — while some trials showed positive signals on surrogate endpoints, the overall evidence quality was limited by methodological concerns and inconsistent outcome reporting.[4] This Cochrane assessment does not conclude that cerebrolysin is ineffective, but rather that available evidence does not yet provide certainty about meaningful clinical benefit. Similarly, cerebrolysin TBI research has shown promising preclinical and clinical signals, though definitive evidence of efficacy remains under investigation.

Mureșanu et al. (2022) offered a more favourable assessment, presenting clinical trial data demonstrating improvements in neurological outcomes and functional recovery.[5] The neuroprotection evidence for cerebrolysin is therefore characterised by a tension between positive individual trial results and cautious systematic review conclusions. Homberg et al. (2025) further demonstrated cerebrolysin’s potential in a randomised pilot study showing enhanced recovery of nonfluent aphasia after acute ischaemic stroke when combined with speech therapy.[8]

Cognitive & Nootropic Support Context

Cognitive and nootropic support represents the second major research domain for cerebrolysin, primarily through studies in vascular dementia and Alzheimer’s disease. The cerebrolysin nootropic research interest stems from its neurotrophic factor mimicry: BDNF and GDNF are critically involved in synaptic plasticity, memory consolidation, and maintenance of cholinergic neurons progressively lost in dementia — providing a mechanistic basis for cerebrolysin’s relevance.

The Cochrane systematic review by Cui et al. (2019) evaluated cerebrolysin for vascular dementia and found possible benefit on cognitive outcomes, though evidence was rated as low-certainty.[6] While some trials showed improvements on cognitive assessment scales, clinical significance was uncertain and overall evidence quality was limited by small sample sizes and risk of bias.

Wang et al. (2024) conducted a network meta-analysis comparing neuroprotective agents for improving neurological function in acute ischaemic stroke, providing comparative context for cerebrolysin.[7] For the cognitive and nootropic support evidence landscape, cerebrolysin’s position is notable — few neurotrophic preparations have been subjected to Cochrane-level systematic review for cognitive outcomes.

Cerebrolysin Benefits

The research-documented cerebrolysin benefits should be interpreted within the context of the available evidence, including both supportive trial data and the more cautious conclusions of Cochrane systematic reviews:

• Multi-pathway neurotrophic support: cerebrolysin delivers peptide fragments mimicking multiple endogenous neurotrophic factors (BDNF, GDNF, CNTF), engaging several neuroprotective signalling cascades simultaneously.[1]
• Extensive clinical evidence base: one of the most studied neurotrophic preparations globally, with randomised controlled trials across stroke, TBI, and dementia populations — a substantially larger clinical dataset than most peptide research compounds.
• Regulatory approval in 30+ countries: approved for clinical use in neurological conditions across Europe, Asia, and Latin America, providing real-world usage data alongside controlled trial evidence.
• Multiple Cochrane systematic reviews: subjected to independent systematic review for both acute ischaemic stroke and vascular dementia — an unusual level of evidence scrutiny for a neurotrophic preparation.[4][6]
• Studied across multiple neurological conditions: ischaemic stroke, traumatic brain injury, vascular dementia, Alzheimer’s disease, and post-stroke aphasia recovery.[8]
• Standardised manufacturing process: produced through controlled enzymatic proteolysis of porcine brain tissue with defined quality parameters, providing batch-to-batch consistency for a biological preparation.

Cerebrolysin Side Effects

The clinical trial literature generally reports a favourable cerebrolysin side effects profile. Across multiple randomised controlled trials, cerebrolysin has been associated with mild and transient adverse effects:

• Common reported effects: dizziness, headache, and injection site reactions.
• Uncommon reported effects: agitation, insomnia, nausea — observed at low frequency.
• Biological product considerations: as a porcine-derived preparation, theoretical immunogenicity concerns exist, though clinically significant allergic reactions have been rarely reported.
• Cochrane safety assessment: both Cochrane reviews noted a generally acceptable safety profile with no major safety signals.[4][6]

The safety data should be contextualised by the same methodological limitations affecting the efficacy evidence. As a biological product, cerebrolysin carries inherent quality considerations that differ from synthetic peptides like CJC-1295 or GHRP-2.

Half-Life

The concept of half-life does not apply to cerebrolysin in the conventional pharmacokinetic sense. Unlike a defined single compound — for example, semaglutide with its well-characterised 168-hour half-life — cerebrolysin is a complex mixture of hundreds of peptide fragments and free amino acids, each with potentially different absorption, distribution, metabolism, and elimination profiles.

The biological activity of cerebrolysin is mediated through neurotrophic signalling cascades that extend well beyond the plasma clearance window of individual peptide components. Once the peptide fragments engage their respective receptor systems (TrkB, GFRα, CNTFRα), the downstream intracellular signalling — including gene expression changes, protein synthesis, and synaptic remodelling — continues for hours to days. This is consistent with the general pharmacology of neurotrophic factors, where the signalling event is brief but the biological response is sustained through transcriptional and structural changes.

Limits of Current Evidence

This section is essential for responsible interpretation of the cerebrolysin evidence base. Despite a large body of clinical research, significant limitations exist that should inform any assessment of the compound:

• Not FDA approved: cerebrolysin has not received approval from the FDA or MHRA. Cerebrolysin UK availability is limited to research-use-only status, as the MHRA has not licensed it for clinical use. Its approval in 30+ countries reflects different regulatory standards and evidence thresholds across jurisdictions.
• Cochrane review conclusions are cautious: the Cochrane review for acute ischaemic stroke (Ziganshina et al. 2023) found uncertain evidence of clinical benefit, while the vascular dementia review (Cui et al. 2019) rated the evidence as low-certainty.[4][6] These independent assessments temper the positive signals from individual trials.
• Geographic concentration of positive trials: many of the most positive RCTs were conducted in countries where cerebrolysin is already approved and commercially available, introducing potential bias in study design, conduct, and interpretation.
• Heterogeneous trial designs: outcome measures, treatment durations, severity populations, and comparator conditions vary substantially across the literature.
• Biological product variability: while manufacturing is standardised, batch-to-batch composition may vary within defined parameters — a concern that does not apply to synthetic peptides like epithalon or Pal-GHK.
• Mechanism attribution: because cerebrolysin contains hundreds of peptide fragments, attributing clinical effects to specific molecular components is extremely difficult.
• No consensus on optimal indications: despite decades of research, no definitive consensus exists on which patient populations benefit most.

Verdict

Cerebrolysin occupies a unique and somewhat paradoxical position in the neurotrophic peptide landscape. It is the most clinically studied multi-peptide neurotrophic preparation in existence, with approval in over 30 countries and scrutiny from multiple Cochrane systematic reviews. Any comprehensive cerebrolysin review of the evidence base must acknowledge that it includes randomised controlled trials across stroke, TBI, and dementia populations — a breadth unusual in this field.

Yet the conclusions remain uncertain. The Cochrane reviews — the gold standard for evidence synthesis — found uncertain benefit for ischaemic stroke and low-certainty evidence for vascular dementia. This disconnect between volume of research and certainty of conclusions reflects genuine challenges in neurotrophic agent research: heterogeneous trial designs, variable outcome measures, and the inherent difficulty of demonstrating clear clinical benefit in complex neurological conditions.

The multi-target approach through neurotrophic factor mimicry is pharmacologically rational for conditions involving multi-pathway neuronal damage. However, the mixed Cochrane findings and absence of FDA or MHRA approval mean that researchers should interpret the evidence cautiously. For the broader context of neuroprotection and cognitive support research, cerebrolysin serves as an important reference point — demonstrating both the potential and the evidentiary challenges of neurotrophic peptide interventions. Related research compounds include Selank for neuropeptide-based approaches, and GHK-Cu for peptide-mediated tissue support.

FAQ

What is Cerebrolysin?

Cerebrolysin is a standardised preparation of low-molecular-weight neuropeptides and free amino acids derived from porcine (pig) brain tissue. It is not a single synthetic peptide but a biological mixture manufactured by EVER Neuro Pharma (Austria). It contains peptide fragments with neurotrophic factor-like activity — mimicking the brain’s own growth factors — and is one of the most clinically studied neurotrophic preparations globally.[1][2]

Is Cerebrolysin FDA approved?

No. Cerebrolysin is not approved by the FDA (United States) or MHRA (United Kingdom). It is approved in over 30 countries across Europe, Asia, and Latin America for neurological conditions including stroke recovery, traumatic brain injury, and dementia. In the US and UK, it is classified as a research-use-only compound.

What conditions is Cerebrolysin studied for?

Cerebrolysin has been studied primarily for ischaemic stroke recovery, traumatic brain injury (TBI), vascular dementia, and Alzheimer’s disease. The clinical evidence includes randomised controlled trials across these indications, as well as Cochrane systematic reviews for acute ischaemic stroke and vascular dementia.[4][6] More recent research has also explored its potential in post-stroke aphasia recovery.[8]

Is Cerebrolysin a single peptide?

No. Cerebrolysin is a complex biological mixture containing hundreds of low-molecular-weight peptide fragments (all under 10 kDa) plus free amino acids. It is produced through standardised enzymatic proteolysis of porcine brain tissue. This distinguishes it from defined single-sequence peptides like BPC-157 or TB-500.

What do Cochrane reviews say about Cerebrolysin?

Two Cochrane systematic reviews have evaluated cerebrolysin. Ziganshina et al. (2023) reviewed cerebrolysin for acute ischaemic stroke and found the evidence for clinical benefit to be uncertain.[4] Cui et al. (2019) reviewed cerebrolysin for vascular dementia and found possible benefit on cognitive outcomes, though the evidence was rated as low-certainty.[6] Both reviews noted methodological concerns across the included trials.

Is Cerebrolysin available in the UK?

Cerebrolysin is not approved or commercially available for clinical use in the United Kingdom. Cerebrolysin UK status remains research-use-only, as it is not licensed by the MHRA. In the UK context, it is considered a research compound. It is approved and commercially available in over 30 other countries, predominantly in continental Europe, Asia, and Latin America.

How does Cerebrolysin differ from other neurotrophic compounds?

Cerebrolysin is unique in being a multi-peptide biological preparation rather than a single synthetic compound. While peptides like Selank and Gonadorelin are defined synthetic neuropeptides with specific molecular targets, cerebrolysin contains a complex mixture of peptide fragments that simultaneously mimic multiple endogenous neurotrophic factors (BDNF, GDNF, CNTF). This multi-target approach is pharmacologically distinct and means that cerebrolysin’s effects cannot be attributed to a single mechanism.[1]

References

1. Rejdak K, et al. Modulation of neurotrophic factors in the treatment of dementia, stroke and TBI: Effects of Cerebrolysin. Med Res Rev. 2023;43(5):1668-1700. PMID: 37052231
2. Fiani B, et al. Cerebrolysin for stroke, neurodegeneration, and traumatic brain injury: review of the literature and outcomes. Neurol Sci. 2021;42(4):1345-1353. PMID: 33515100
3. Cook AM, et al. Update on Neuroprotection after Traumatic Brain Injury. CNS Drugs. 2025;39(5):443-462. PMID: 40087248
4. Ziganshina LE, et al. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev. 2023;10:CD007026. PMID: 37818733
5. Mureșanu DF, et al. Role and Impact of Cerebrolysin for Ischemic Stroke Care. J Clin Med. 2022;11(5):1273. PMID: 35268364
6. Cui S, et al. Cerebrolysin for vascular dementia. Cochrane Database Syst Rev. 2019;11:CD008900. PMID: 31710397
7. Wang Y, et al. Comparative efficacy of neuroprotective agents for improving neurological function and prognosis in acute ischemic stroke: a network meta-analysis. Front Neurosci. 2024;18:1507034. PMID: 39834702
8. Homberg V, et al. Speech Therapy Combined With Cerebrolysin in Enhancing Nonfluent Aphasia Recovery After Acute Ischemic Stroke: ESCAS Randomized Pilot Study. Stroke. 2025;56(4):1053-1061. PMID: 39957612

Semax is a synthetic heptapeptide analog of ACTH(4-10) — the fragment of adrenocorticotropic hormone (ACTH) responsible for cognitive and neurotrophic effects, stripped of the hormonal segments that drive adrenal cortex activation. The semax peptide was developed at the Institute of Molecular Genetics, Russian Academy of Sciences, with the specific goal of isolating nootropic and neuroprotective activity from full-length ACTH while eliminating cortisol-stimulating properties. Its sequence — Met-Glu-His-Phe-Pro-Gly-Pro — retains the ACTH(4-10) core with a C-terminal Pro-Gly-Pro extension engineered for metabolic stability.

What distinguishes semax from most investigational peptides is its regulatory history: it has been approved in Russia since 2001 as a nootropic and neuroprotective nasal spray, giving it a level of clinical validation that most research peptides lack. Semax nootropic research centres on its ability to upregulate brain-derived neurotrophic factor (BDNF) and activate dopaminergic and serotonergic systems — mechanisms that connect it to synaptic plasticity, learning, memory, and neuroprotection after ischemic injury.

Despite its Russian approval and a growing body of English-language mechanistic research, semax remains unapproved by the FDA and EMA. It occupies an unusual position: more clinically validated than most research peptides, but without the large-scale Western clinical trial data that would establish it in international regulatory frameworks. For context, compounds like BPC-157 and GHK-Cu share investigational neuroprotective profiles through different mechanisms.

Compound Profile

What Does Semax Actually Do?

Semax enhances cognitive function primarily through upregulation of brain-derived neurotrophic factor (semax BDNF). BDNF is the brain’s principal neurotrophin — the protein that drives synaptic plasticity, neuronal survival, and the formation of new synaptic connections that underlie learning and memory. By increasing BDNF and its receptor TrkB in the hippocampus, semax activates the molecular machinery of cognitive enhancement at its most fundamental level.[1] This positions it as one of the most mechanistically rational semax nootropic compounds in the research peptide space.

Beyond BDNF, semax activates dopaminergic and serotonergic neurotransmitter systems — the two pathways most directly associated with motivation, focus, mood regulation, and reward processing.[2] This dual neurotransmitter modulation, combined with neurotrophic factor upregulation, creates a multi-mechanism cognitive support profile. Crucially, despite being derived from ACTH, semax does not stimulate cortisol or activate the adrenal cortex — the hormonal segments responsible for ACTH’s stress-hormone effects are absent from the ACTH(4-10) fragment.

The second major research domain is semax neuroprotective activity. Preclinical studies demonstrate that semax activates neurotrophic gene transcription after cerebral ischemia — the oxygen-deprived conditions of stroke.[3] This neuroprotective profile has driven its clinical use in Russia for both cognitive support and ischemic stroke recovery. Semax operates through a fundamentally different mechanism than tissue-repair peptides like BPC-157 or TB-500, targeting neurotrophin expression rather than angiogenesis or inflammation.

How Semax Works

The pharmacological logic of semax begins with the structure of ACTH itself. Full-length ACTH (39 amino acids) drives cortisol production through the adrenal cortex — but the cognitive and neurotrophic effects reside specifically in the ACTH 4-10 fragment (positions 4 through 10 of the ACTH sequence). By isolating this fragment and discarding the N-terminal (1-3) and C-terminal (11-39) segments, semax retains the cognitive-active region while eliminating hormonal activity entirely. The C-terminal Pro-Gly-Pro extension was engineered to prevent rapid enzymatic degradation, extending the functional half-life of what would otherwise be a rapidly cleared peptide fragment.

Dolotov et al. (2006) demonstrated that semax regulates BDNF and TrkB expression in the rat hippocampus — providing direct evidence that the ACTH 4-10 fragment drives neurotrophic signalling in the brain region most critical for memory and learning.[1] Eremin et al. (2005) established that semax activates both dopaminergic and serotonergic brain systems in rodents, identifying the neurotransmitter pathways that complement its neurotrophic activity.[2] Dmitrieva et al. (2010) extended the mechanistic picture to neuroprotection, showing that semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia — demonstrating that the compound upregulates the brain’s own repair machinery in response to ischemic injury.[3]

This mechanism — neurotrophic factor upregulation combined with neurotransmitter system activation — is distinct from most other peptide mechanisms. Where growth hormone secretagogues like ipamorelin and GHRP-2 operate through the GH-IGF-1 axis, and tissue-repair peptides like TB-500 work through actin regulation, semax acts directly on central nervous system neurotrophin pathways.

Cognitive & Nootropic Support Context

The cognitive and nootropic support profile of semax is its primary research domain — and the area where the mechanistic evidence is strongest. BDNF upregulation is the central mechanism: brain-derived neurotrophic factor drives long-term potentiation (LTP), the cellular process underlying memory consolidation and learning. By increasing both BDNF and its receptor TrkB in the hippocampus, semax activates the molecular substrate of cognitive enhancement at a foundational level.[1]

Manchenko et al. (2010) characterised nootropic and analgesic effects of semax across different experimental paradigms, confirming cognitive performance improvements in preclinical models.[4] Panikratova et al. (2020) applied functional connectomic analysis to study semax’s effects on brain network organisation, providing neuroimaging-level evidence of altered functional connectivity consistent with enhanced cognitive processing.[5] The combined dopaminergic and serotonergic activation adds motivational and mood-regulatory dimensions to the cognitive profile — a multi-pathway nootropic mechanism that distinguishes semax from compounds acting on single neurotransmitter systems.

For context within the peptide landscape: most peptides studied for cognitive effects operate indirectly — through GH-mediated neuroprotection (sermorelin, CJC-1295) or through tissue-repair mechanisms with secondary neural benefits (BPC-157). Semax is unusual in targeting CNS neurotrophin pathways directly, making it one of the most mechanism-specific nootropic peptides in the current research landscape. The peptide epithalon provides an interesting parallel — while its mechanism (telomerase activation) is entirely different, it similarly targets a specific molecular pathway rather than operating through broad systemic effects.

Neuroprotection Context

The neuroprotection research on semax centres on its ability to activate the brain’s endogenous repair machinery after ischemic injury. Cerebral ischemia — the oxygen deprivation that occurs during stroke — triggers widespread neuronal death, and compounds that can upregulate neurotrophic gene expression during the critical post-ischemic window represent a significant research target. Dmitrieva et al. (2010) demonstrated that semax activates transcription of neurotrophins and their receptor genes after experimental cerebral ischemia, providing evidence for a direct neuroprotective mechanism.[3]

Filippenkov et al. (2024) advanced this research significantly, showing that ACTH-like peptides including semax can compensate for disrupted brain gene expression profiles following experimental stroke — essentially demonstrating that semax partially normalises the catastrophic transcriptomic changes caused by ischemia.[6] Glazova et al. (2021) extended semax’s neuroprotective profile to developmental neurotoxicity, showing that the compound attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure — suggesting neuroprotective relevance beyond acute ischemic injury.[7]

Most recently, Liu et al. (2025) identified a novel neuroprotective mechanism: semax targets the μ-opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury, opening a new mechanistic dimension beyond the established BDNF/neurotrophin pathway.[8] This expanding mechanistic profile — from BDNF upregulation to gene expression normalisation to opioid receptor modulation — suggests that semax neuroprotective effects may operate through multiple convergent pathways. For comparison, GHK-Cu has also shown neuroprotective potential through entirely different mechanisms (gene expression modulation and anti-inflammatory activity).

Semax Benefits

The semax benefits profile reflects its dual nootropic-neuroprotective mechanism, supported by both preclinical research and Russian clinical use:

• BDNF upregulation: Directly increases brain-derived neurotrophic factor and TrkB receptor expression in the hippocampus — the molecular foundation of synaptic plasticity and memory formation.[1]
• Neuroprotective in ischemia models: Activates neurotrophic gene transcription after cerebral ischemia, partially normalising gene expression disrupted by stroke.[3][6]
• Nootropic without hormonal effects: Retains the cognitive-active ACTH(4-10) fragment while eliminating adrenal cortex stimulation — cognitive enhancement without cortisol elevation.
• No cortisol stimulation: Despite being derived from ACTH, semax does not activate the HPA axis or stimulate cortisol release — a critical distinction from full-length ACTH.
• Dopamine and serotonin modulation: Activates both dopaminergic and serotonergic systems, supporting motivation, focus, and mood regulation.[2]
• Approved medication in Russia: Clinical approval since 2001 as a nootropic nasal spray provides a level of regulatory validation absent for most research peptides.
• Well-characterised mechanism: The ACTH-derived pharmacological rationale is well-understood, with multiple published mechanistic studies in English-language journals.[1][2][3]
• Expanding research profile: Recent studies continue to identify novel mechanisms including gene expression normalisation post-stroke and μ-opioid receptor modulation.[6][8]

Semax Side Effects

The semax side effects profile is generally favourable based on available data:

• Generally well-tolerated: Russian clinical experience since 2001 has not identified major safety concerns, supporting a favourable tolerability profile within the context of its approved use.
• No hormonal (adrenal) side effects: Unlike full-length ACTH, semax does not stimulate cortisol, aldosterone, or other adrenal hormones — the hormonal segments are absent from the ACTH(4-10) fragment.
• Nasal irritation: The most commonly noted effect with intranasal formulations — local irritation at the site of application, typically mild and transient.
• Limited Western safety data: Most safety characterisation derives from Russian clinical use rather than Western regulatory-grade safety studies. The absence of large-scale Western pharmacovigilance data is a limitation.
• Short duration of action: The short half-life means effects dissipate rapidly — a potential limitation for sustained cognitive support but also a safety advantage in terms of reversibility.

The semax side effects profile compares favourably to many GH-axis peptides that produce broader systemic effects. Unlike GHRP-6 or GHRP-2, which stimulate cortisol, appetite, and other hormonal pathways, semax’s CNS-targeted mechanism produces a narrower and generally milder side effect profile. The principal caveat is not the presence of known side effects but the absence of comprehensive Western safety data.

Half-Life

Semax has a short plasma half-life measured in minutes — characteristic of small peptide fragments that are rapidly cleared by circulating peptidases. However, the C-terminal Pro-Gly-Pro extension was specifically engineered to improve metabolic stability compared to the native ACTH(4-10) fragment, which would otherwise be degraded within seconds to minutes. This stabilisation strategy is pharmacologically analogous to how CJC-1295 uses Drug Affinity Complex (DAC) technology to extend the half-life of GHRH analogs, though the mechanisms differ.

The short circulating half-life does not necessarily limit functional duration: semax’s downstream effects — BDNF upregulation, neurotrophic gene transcription, neurotransmitter system modulation — operate on longer biological timescales than the peptide’s plasma presence. This is consistent with the principle that many peptide signalling molecules act as triggers rather than sustained effectors, initiating cascades that persist beyond the compound’s circulating presence. For comparison across peptide half-lives: ipamorelin has approximately a 2-hour half-life, sermorelin is 10-20 minutes, and epithalon operates on similarly short timescales with longer-duration downstream effects.

Limits of Current Evidence

• Not FDA or EMA approved: Semax has no regulatory approval outside Russia and former Soviet states. Unlike semaglutide and liraglutide (FDA-approved GLP-1 agonists) or tesamorelin (FDA-approved GHRH analog), semax lacks Western regulatory validation.
• Russian clinical approval provides some validation: Approval since 2001 as a nootropic nasal spray represents real regulatory review, but Russian approval standards differ from FDA/EMA requirements and may not satisfy Western evidence thresholds.
• More English-language data than many Russian-developed peptides: Semax has a growing body of English-language mechanistic publications, but still limited large-scale Western clinical trial data. Most human outcome data exists in Russian-language literature.
• Strong preclinical data, limited clinical translation: Animal model data for ischemia, BDNF upregulation, and behavioural effects is robust, but human outcome trials in Western literature are scarce. The gap between preclinical promise and clinical validation remains significant.
• Well-understood ACTH-derived mechanism provides confidence: The pharmacological rationale — isolating the cognitive-active ACTH(4-10) fragment — is grounded in well-established ACTH biology, which provides mechanistic confidence even where clinical data is limited.
• Long-term safety data is limited to Russian pharmacovigilance: Multi-year safety profiles from Western regulatory-grade monitoring do not exist.

Verdict

Semax is one of the most pharmacologically rational nootropic peptides in the research landscape. By isolating the cognitive-active ACTH 4-10 fragment — the region of adrenocorticotropic hormone responsible for neurotrophic and nootropic effects — and stabilising it with a Pro-Gly-Pro C-terminal extension, the semax peptide achieves targeted neurotrophic and neuroprotective activity without hormonal cross-talk. The semax BDNF upregulation data is compelling and mechanistically well-characterised, and its activation of dopaminergic and serotonergic systems provides a multi-pathway cognitive support profile.[1][2]

The Russian clinical approval since 2001 adds a layer of regulatory weight that most research peptides lack entirely — this is a compound that has been prescribed and monitored in clinical settings for over two decades, not merely studied in laboratory conditions. The expanding English-language research base — from BDNF upregulation to post-ischemic gene expression normalisation to spinal cord injury recovery — demonstrates a compound with a deepening rather than narrowing evidence profile.[3][6][8]

This semax review of the published evidence makes the limitation clear: outside Russia, semax remains investigational. The absence of FDA/EMA approval and large-scale Western clinical trials means that international regulatory frameworks do not recognise its efficacy claims. For researchers and clinicians evaluating nootropic peptides, semax presents a compound where the mechanistic rationale is strong, the Russian clinical experience is extensive, but the Western evidentiary standard has not yet been met. This positions it as one of the most interesting compounds to watch as the English-language evidence base continues to develop. The semax vs selank comparison is particularly instructive: both are Russian-developed nootropic peptides from the same institute, but semax targets BDNF/neurotrophin pathways while selank targets anxiolytic/immunomodulatory pathways — complementary rather than competing mechanisms.

FAQ

What is Semax?

Semax is a synthetic heptapeptide analog of ACTH(4-10) — the fragment of adrenocorticotropic hormone responsible for cognitive and neurotrophic effects. It was developed at the Institute of Molecular Genetics, Russian Academy of Sciences, and has been approved in Russia since 2001 as a nootropic and neuroprotective nasal spray. It is not approved by the FDA or EMA.

Is Semax the same as ACTH?

No. Semax contains only the ACTH(4-10) fragment — seven amino acids from the cognitive-active region of the 39-amino-acid ACTH molecule. The segments responsible for adrenal cortex stimulation and cortisol production (positions 1-3 and 11-39) are absent. Semax retains nootropic and neurotrophic effects while eliminating hormonal activity.[1]

Does Semax increase cortisol?

No. Despite being derived from ACTH (which is the primary driver of cortisol production), semax does not stimulate the adrenal cortex or increase cortisol levels. The ACTH(4-10) fragment lacks the structural elements required for adrenal activation — this separation of cognitive from hormonal effects is the core pharmacological design principle of semax.

What is the difference between Semax and Selank?

Both are synthetic heptapeptides developed at the same Russian institute (Institute of Molecular Genetics, RAS) and approved in Russia as nasal sprays. However, they target different mechanisms: semax is an ACTH(4-10) analog that upregulates BDNF and activates dopaminergic/serotonergic systems for nootropic and neuroprotective effects. Selank is a tuftsin analog that modulates enkephalin metabolism for anxiolytic and immunomodulatory effects. They are complementary rather than interchangeable compounds.

Is Semax approved anywhere?

Yes. Semax has been approved in Russia since 2001 as a nootropic and neuroprotective nasal spray. It is not approved by the FDA, EMA, or other Western regulatory agencies. It is not classified as a controlled substance internationally.

Does Semax increase BDNF?

Yes. Dolotov et al. (2006) demonstrated that semax regulates BDNF and TrkB receptor expression in the rat hippocampus — providing direct evidence of neurotrophic factor upregulation. BDNF upregulation is considered the primary mechanistic basis of semax’s nootropic and neuroprotective effects.[1]

Is Semax FDA approved?

No. Semax is not FDA-approved for any indication. It remains a research compound in Western regulatory contexts. Its only regulatory approval is in Russia, where it has been an approved medication since 2001. For FDA-approved peptide-class therapeutics, see semaglutide, liraglutide, or tesamorelin.

References

1. Dolotov OV, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117(1):54-60. PMID: 16996037
2. Eremin KO, et al. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochem Res. 2005;30(12):1493-1500. PMID: 16362768
3. Dmitrieva VG, et al. Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cell Mol Neurobiol. 2010;30(1):71-79. PMID: 19633950
4. Manchenko DM, et al. Nootropic and analgesic effects of Semax following different routes of administration. Ross Fiziol Zh. 2010;96(10):1014-1023. PMID: 21268834
5. Panikratova YR, et al. Functional Connectomic Approach to Studying Selank and Semax Effects. Dokl Biol Sci. 2020;490(1):9-11. PMID: 32342318
6. Filippenkov IB, et al. ACTH-like Peptides Compensate Rat Brain Gene Expression Profile Disrupted by Ischemia a Day After Experimental Stroke. Biomedicines. 2024;13(1):18. PMID: 39767736
7. Glazova NY, et al. Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure. Neuropeptides. 2021;86:102117. PMID: 33418449
8. Liu R, et al. Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury. Br J Pharmacol. 2025;182(22). PMID: 40692165

Medical Disclaimer: This page is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Semax is not approved by the FDA for any indication. Always consult a qualified healthcare professional before making any decisions related to your health. The information presented reflects published research and does not imply endorsement of any compound for human use outside of supervised clinical settings.